Literature DB >> 20020274

The danger hypothesis applied to idiosyncratic drug reactions.

Jinze Li1, Jack P Uetrecht.   

Abstract

The danger hypothesis has had a profound effect on the way immunologists view the immune response. This hypothesis proposes that the major determinant of whether an immune response is mounted against some agent is determined by whether that agent causes some type of cell damage. Assuming that most idiosyncratic drug reactions (IDRs) are immune-mediated, this hypothesis also has the potential to explain many aspects of the mechanism of these adverse drug reactions. For example, most IDRs appear to be caused by chemical metabolites rather than the parent drug, but not all drugs that form reactive metabolites are associated with a significant incidence of IDRs. Therefore, using the danger hypothesis, one feature of a drug candidate that may predict whether it causes an IDR is whether the drug, or more likely its reactive metabolites, cause cell damage. Although the range of molecules that can act as danger signals is unknown, the most attractive candidates are high mobility group box 1 protein (HMGB1), heat shock proteins, and S100 proteins. These molecules act through the same receptors (toll-like receptors) as pathogen-associated molecules that stimulate the immune system. Therefore, other environmental factors such as infections or trauma might determine which patients would be at increased risk for IDRs. Although there are examples where this appears to be the case, in most cases there are no obvious environmental factors that determine IDR risk. In addition, in animal models of immune-mediated reactions, stimulation of toll-like receptors often does not increase the immune response, and depending on the timing, it can actually be protective. Therefore, there may be additional unknown control mechanisms that are involved. A better understanding of these fundamental immune mechanisms has the potential to have a significant impact on many areas of medicine.

Entities:  

Mesh:

Year:  2010        PMID: 20020274     DOI: 10.1007/978-3-642-00663-0_18

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  14 in total

1.  [Bone marrow hematopoiesis. Evaluation of the myelogram].

Authors:  E B Vladimirskaia
Journal:  Gematol Transfuziol       Date:  1990-08       Impact factor: 0.172

Review 2.  Molecular mechanisms underlying chemical liver injury.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Expert Rev Mol Med       Date:  2012-02-03       Impact factor: 5.600

3.  Allergic host defences.

Authors:  Noah W Palm; Rachel K Rosenstein; Ruslan Medzhitov
Journal:  Nature       Date:  2012-04-25       Impact factor: 49.962

4.  Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.

Authors:  Michael A Norcross; Shen Luo; Li Lu; Michael T Boyne; Mary Gomarteli; Aaron D Rennels; Janet Woodcock; David H Margulies; Curtis McMurtrey; Stephen Vernon; William H Hildebrand; Rico Buchli
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

Review 5.  Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management.

Authors:  M Mosedale; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  2017-01-11       Impact factor: 6.875

6.  Editor's Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach.

Authors:  Merrie Mosedale; Yunjung Kim; William J Brock; Sharin E Roth; Tim Wiltshire; J Scott Eaddy; Gregory R Keele; Robert W Corty; Yuying Xie; William Valdar; Paul B Watkins
Journal:  Toxicol Sci       Date:  2017-04-01       Impact factor: 4.849

Review 7.  Managing the challenge of chemically reactive metabolites in drug development.

Authors:  B Kevin Park; Alan Boobis; Stephen Clarke; Chris E P Goldring; David Jones; J Gerry Kenna; Craig Lambert; Hugh G Laverty; Dean J Naisbitt; Sidney Nelson; Deborah A Nicoll-Griffith; R Scott Obach; Philip Routledge; Dennis A Smith; Donald J Tweedie; Nico Vermeulen; Dominic P Williams; Ian D Wilson; Thomas A Baillie
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

Review 8.  Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation.

Authors:  Mitchell R McGill; Hartmut Jaeschke
Journal:  Expert Rev Mol Diagn       Date:  2018-08-13       Impact factor: 5.225

9.  Cutaneous drug hypersensitivity: immunological and genetic perspective.

Authors:  Kisalay Ghosh; Gautam Banerjee; Asok Kumar Ghosal; Jayoti Nandi
Journal:  Indian J Dermatol       Date:  2011-03       Impact factor: 1.494

10.  Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical Proteins.

Authors:  Benjamin J Andrick; Alexandra I Schwab; Brianna Cauley; Lauren A O'Donnell; Wilson S Meng
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.